Jazz Pharmaceuticals (JAZZ) Misses Q4 EPS by 16c; offers guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/29/2026
- Wall Street ends lower as Alphabet revenue miss revives AI capex jitters
- Alphabet shares tumble 10% as earnings miss overshadows cloud boom
- Microsoft rises premarket as cloud strength drives earnings beat
- Caterpillar shares slump 10% despite earnings beat amid rapid AI buildout
- DoorDash to acquire Instacart in $17 billion deal
Tweet
Share
E-mail
Get Alerts JAZZ Hot Sheet
Price: $207.83 +1.35%
EPS Growth %: -22.5%
Financial Fact:
Total operating expenses: 237.93M
Today's EPS Names:
PFBX, GOVB, VABK, More
EPS Growth %: -22.5%
Financial Fact:
Total operating expenses: 237.93M
Today's EPS Names:
PFBX, GOVB, VABK, More
Join SI Premium – FREE
Jazz Pharmaceuticals (NASDAQ: JAZZ) reported Q4 EPS of $5.02, $0.16 worse than the analyst estimate of $5.18. Revenue for the quarter came in at $1.01 billion versus the consensus estimate of $1.01 billion.
GUIDANCE:
Jazz Pharmaceuticals sees FY2024 EPS of $18.15-$19.35, versus the consensus of $19.62. Jazz Pharmaceuticals sees FY2024 revenue of $4-4.2 billion, versus the consensus of $4.081 billion.
For earnings history and earnings-related data on Jazz Pharmaceuticals (JAZZ) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- SPS Commerce (SPSC) Tops Q3 EPS by 16c; Offers Guidance
- Alignment Healthcare, Inc. (ALHC) Reports In-Line Q3 EPS; offers guidance
- AptarGroup (ATR) Tops Q3 EPS by 5c
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
